Morroniside Inhibits Inflammatory Bone Loss through the TRAF6-Mediated NF-κB/MAPK Signalling Pathway
Pharmaceuticals · 10.10.2023 · 16 (10) · 1438
DOI: 10.3390/ph16101438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 10.10.2023. Verfasst von Jirimutu Xiao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of New Techniques of Restoration & Reconstruction, Institute of Traumatology & Orthopedics, Nanjing University of Chinese Medicine, Nanjin…. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natinal Natural Science Foundation of China, Jiangsu Provincial Natural Science Foundation of China, Foundation of Jiangsu CM Clinical Innovation Center of Degenerative Bone & Joint Disease (Jiangsu Science and Education of Traditional Chinese Medicine).
Abstract (Originalsprache)
Osteoporosis is a chronic inflammatory disease that severely affects quality of life. Cornus officinalis is a Chinese herbal medicine with various bioactive ingredients, among which morroniside is its signature ingredient. Although anti-bone resorption drugs are the main treatment for bone loss, promoting bone anabolism is more suitable for increasing bone mass. Therefore, identifying changes in bone formation induced by morroniside may be conducive to developing effective intervention methods. In this study, morroniside was found to promote the osteogenic differentiation of bone marrow stem cells (BMSCs) and inhibit inflammation-induced bone loss in an in vivo mouse model of inflammatory bone loss. Morroniside enhanced bone density and bone microstructure, and inhibited the expression of IL6, IL1β, and ALP in serum (p < 0.05). Furthermore, in in vitro experiments, BMSCs exposed to 0–256 μM morroniside did not show cytotoxicity. Morroniside inhibited the expression of IL6 and IL1β and promoted the expression of the osteogenic transcription factors Runx2 and OCN. Furthermore, morroniside promoted osteocalcin and Runx2 expression and inhibited TRAF6-mediated NF-κB and MAPK signaling, as well as osteoblast growth and NF-κB nuclear transposition. Thus, morroniside promoted osteogenic differentiation of BMSCs, slowed the occurrence of the inflammatory response, and inhibited bone loss in mice with inflammatory bone loss.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of New Techniques of Restoration & Reconstruction, Institute of Traumatology & Orthopedics, Nanjing University of Chinese Medicine, Nanjing 210023, China.
- School of Mongolia Medicine, Inner Mongolia Medical University, Hohhot 010110, China.
- School of Chinese Medicine · School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
- Jiangsu CM Clinical Innovation Center of Degenerative Bone & Joint Disease, Wuxi TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Wuxi 214071, China.
ORCID-Profile: Lining Wang
Förderung
- Natinal Natural Science Foundation of China
- Jiangsu Provincial Natural Science Foundation of China
- Foundation of Jiangsu CM Clinical Innovation Center of Degenerative Bone & Joint Disease (Jiangsu Science and Education of Traditional Chinese Medicine)
- Jiangsu Provincial Research and Practice Innovation Program
Zitieren
APA
Xiao, J., Han, Q., Yu, Z., Liu, M., Sun, J., Wu, M., Yin, H., Fu, J., Guo, Y., Wang, L., & Ma, Y. (2023). Morroniside Inhibits Inflammatory Bone Loss through the TRAF6-Mediated NF-κB/MAPK Signalling Pathway. Pharmaceuticals, 16(10), 1438. https://doi.org/10.3390/ph16101438
Vancouver
Xiao J, Han Q, Yu Z, Liu M, Sun J, Wu M, et al. Morroniside Inhibits Inflammatory Bone Loss through the TRAF6-Mediated NF-κB/MAPK Signalling Pathway. Pharmaceuticals. 2023;16(10):1438. doi:10.3390/ph16101438
BibTeX
@article{Xiao2023,
author = {Xiao, Jirimutu and Han, Qiuge and Yu, Ziceng and Liu, Mengmin and Sun, Jie and Wu, Mao and Yin, Heng and Fu, Jingyue and Guo, Yang and Wang, Lining and Ma, Yong},
title = {Morroniside Inhibits Inflammatory Bone Loss through the TRAF6-Mediated NF-κB/MAPK Signalling Pathway},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {10},
pages = {1438},
doi = {10.3390/ph16101438}
}
EUVIMED